

InDex Pharmaceuticals appoints new CFO

March 8, 2017 – InDex Pharmaceuticals Holding AB (publ) today announced that the company has appointed Johan Giléus as new Chief Financial Officer (CFO) from May 1, 2017.

Giléus (born 1965) is working as an independent financial advisor. Previously he spent 25 years with Deloitte, where he among other things as partner headed up the Transaction Services function with some 30 professionals and served on the board of Deloitte Sweden. He has extensive experience of accounting and financial reporting in publicly traded companies and other issues regarding the stock market, risk management and strategic transactions. Giléus participated as a consultant in the work with InDex Pharmaceuticals' IPO during 2016 and has since then advised the company on financial reporting matters as a listed company.

"I am looking forward to work with Johan and welcome him to the InDex management team at this exciting time for the company", says Peter Zerhouni, CEO of InDex Pharmaceuticals. "As a newly listed company it feels very reassuring with Johan's expertise and extensive experience of the public environment."

InDex Pharmaceuticals' current CFO, Per-Olof Gunnesson (born 1945) who has been the CFO since 2003, will remain engaged with the company as a consultant, focusing primarily on contractual issues.

For more information:

Peter Zerhouni, CEO

Phone: +46 8 508 847 35

E-mail: peter.zerhouni@indexpharma.com

InDex Pharmaceuticals in brief

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company's foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company's shares are traded on Nasdaq First North Stockholm. Redeye AB is the company's Certified Adviser. For more information, please visit www.indexpharma.com

Publication

This information is information that InDex Pharmaceuticals Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication through the agency of the contact person set out above at 8:00 CET on March 8, 2017.